Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The utility of 82Rb PET for myocardial viability assessment: Comparison with perfusion-metabolism 82Rb-18F-FDG PET.

Moody JB, Hiller KM, Lee BC, Poitrasson-Rivière A, Corbett JR, Weinberg RL, Murthy VL, Ficaro EP.

J Nucl Cardiol. 2019 Apr;26(2):374-386. doi: 10.1007/s12350-019-01615-0. Epub 2019 Feb 26.

PMID:
30809755
2.

Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2005;5(16):1-167. Epub 2005 Oct 1.

3.

Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2010;10(16):1-80. Epub 2010 Jul 1.

4.

Can nitrogen-13 ammonia kinetic modeling define myocardial viability independent of fluorine-18 fluorodeoxyglucose?

Beanlands RS, deKemp R, Scheffel A, Nahmias C, Garnett ES, Coates G, Johansen HL, Fallen E.

J Am Coll Cardiol. 1997 Mar 1;29(3):537-43.

5.

Low-carbohydrate diet versus euglycemic hyperinsulinemic clamp for the assessment of myocardial viability with 18F-fluorodeoxyglucose-PET: a pilot study.

Soares J Jr, Rodrigues Filho F, Izaki M, Giorgi MC, Catapirra RM, Abe R, Vinagre CG, Cerri GG, Meneghetti JC.

Int J Cardiovasc Imaging. 2014 Feb;30(2):415-23. doi: 10.1007/s10554-013-0324-5. Epub 2013 Nov 20.

PMID:
24253855
6.

Washout of ⁸²Rb as a marker of impaired tissue integrity, obtained by list-mode cardiac PET/CT: relationship with perfusion/metabolism patterns of myocardial viability.

Chien DT, Bravo P, Higuchi T, Merrill J, Bengel FM.

Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1507-15. doi: 10.1007/s00259-011-1820-2. Epub 2011 Apr 29.

PMID:
21528386
7.

Role of quantitative myocardial blood flow and 13N-ammonia washout for viability assessment in ischemic cardiomyopathy.

Benz DC, Ferro P, Safa N, Messerli M, von Felten E, Huang W, Patriki D, Giannopoulos AA, Fuchs TA, Gräni C, Gebhard C, Pazhenkottil AP, Kaufmann PA, Buechel RR.

J Nucl Cardiol. 2019 Mar 20. doi: 10.1007/s12350-019-01684-1. [Epub ahead of print]

PMID:
30895563
8.

Magnetic resonance imaging (MRI) for the assessment of myocardial viability: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2010;10(15):1-45. Epub 2010 Jul 1.

9.

Myocardial viability assessment by PET: (82)Rb defect washout does not predict the results of metabolic-perfusion mismatch.

Stankewicz MA, Mansour CS, Eisner RL, Churchwell KB, Williams BR, Sigman SR, Streeter J, Patterson RE.

J Nucl Med. 2005 Oct;46(10):1602-9.

10.

Myocardial rubidium-82 tissue kinetics assessed by dynamic positron emission tomography as a marker of myocardial cell membrane integrity and viability.

vom Dahl J, Muzik O, Wolfe ER Jr, Allman C, Hutchins G, Schwaiger M.

Circulation. 1996 Jan 15;93(2):238-45.

PMID:
8548894
11.

Assessment of myocardial viability in dysfunctional myocardium by resting myocardial blood flow determined with oxygen 15 water PET.

Nowak B, Schaefer WM, Koch KC, Kaiser HJ, Block S, Knackstedt C, Zimny M, vom Dahl J, Buell U.

J Nucl Cardiol. 2003 Jan-Feb;10(1):34-45.

PMID:
12569329
14.

Is chronically dysfunctional yet viable myocardium distal to a severe coronary stenosis hypoperfused?

Hughes GC, Landolfo CK, Yin B, DeGrado TR, Coleman RE, Landolfo KP, Lowe JE.

Ann Thorac Surg. 2001 Jul;72(1):163-8.

PMID:
11465172
15.

Status of F-18 fluorodeoxyglucose uptake in normal and hibernating myocardium after glucose and insulin loading.

Sarikaya I, Elgazzar AH, Alfeeli MA, Sharma PN, Sarikaya A.

J Saudi Heart Assoc. 2018 Apr;30(2):75-85. doi: 10.1016/j.jsha.2017.07.001. Epub 2017 Jul 10.

16.

Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium.

Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, Hachamovitch R.

Circ Cardiovasc Imaging. 2013 May 1;6(3):363-72. doi: 10.1161/CIRCIMAGING.112.000138. Epub 2013 Apr 17.

PMID:
23595888
17.

Identification of ischemic and hibernating myocardium: feasibility of post-exercise F-18 deoxyglucose positron emission tomography.

Marwick TH, MacIntyre WJ, Salcedo EE, Go RT, Saha G, Beachler A.

Cathet Cardiovasc Diagn. 1991 Feb;22(2):100-6.

PMID:
2009557
18.

Dobutamine-induced contractile reserve in stunned, hibernating, and scarred myocardium in patients with ischemic cardiomyopathy.

Schinkel AF, Bax JJ, van Domburg R, Elhendy A, Valkema R, Vourvouri EC, Sozzi FB, Roelandt JR, Poldermans D.

J Nucl Med. 2003 Feb;44(2):127-33.

19.

Prognostic performance of quantitative PET tools for stratification of patients with ischemic cardiomyopathy undergoing myocardial viability assessment.

Santana CA, Faber TL, Soler-Peter M, Sanyal R, Esteves FP, Ornelas M, Folks RD, Verdes L, Santana LF, Candell-Riera J, Garcia EV.

Nucl Med Commun. 2008 Nov;29(11):970-81. doi: 10.1097/MNM.0b013e3283073b60.

PMID:
18836375

Supplemental Content

Support Center